Holen Sie sich die Stockscreener-App
130.69
0.15%
0.19
Handel nachbörslich:
130.10
-0.59
-0.45%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt GILD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$130.50
Offen:
$131.36
24-Stunden-Volumen:
5.57M
Relative Volume:
0.92
Marktkapitalisierung:
$162.26B
Einnahmen:
$29.79B
Nettoeinkommen (Verlust:
$9.22B
KGV:
17.78
EPS:
7.3494
Netto-Cashflow:
$10.23B
1W Leistung:
-1.77%
1M Leistung:
-3.81%
6M Leistung:
+4.56%
1J Leistung:
+19.78%
1-Tages-Spanne:
$129.49
$131.95
1-Wochen-Bereich:
$128.34
$134.65
52-Wochen-Spanne:
$104.46
$157.29
Gilead Sciences Inc Stock (GILD) Company Profile
Firmenname
Gilead Sciences Inc
Sektor
Telefon
(650) 574-3000
Adresse
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD vs LLY, JNJ, ABBV, AZN, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
130.69 | 160.99B | 29.79B | 9.22B | 10.23B | 7.3494 |
LLY
Lilly Eli Co
|
1,018.87 | 881.12B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
229.32 | 551.06B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
212.30 | 369.98B | 62.82B | 3.60B | 19.98B | 2.0274 |
AZN
Astrazeneca Plc
|
187.46 | 285.23B | 60.48B | 10.40B | 8.05B | 3.3297 |
NVS
Novartis Ag Adr
|
150.45 | 284.59B | 54.66B | 13.58B | 16.05B | 7.0171 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-10 | Eingeleitet | Jefferies | Buy |
| 2026-02-20 | Eingeleitet | Barclays | Equal Weight |
| 2026-02-11 | Bestätigt | Needham | Buy |
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2025-11-24 | Fortgesetzt | Truist | Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-08-19 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | Hochstufung | Truist | Hold → Buy |
| 2025-07-25 | Hochstufung | Needham | Hold → Buy |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-03-04 | Bestätigt | Oppenheimer | Outperform |
| 2025-02-18 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-02-13 | Hochstufung | DZ Bank | Hold → Buy |
| 2025-01-10 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-14 | Eingeleitet | Citigroup | Buy |
| 2024-11-08 | Herabstufung | Maxim Group | Buy → Hold |
| 2024-10-21 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-10-07 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | Bestätigt | Maxim Group | Buy |
| 2024-04-24 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2024-02-22 | Herabstufung | Truist | Buy → Hold |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-09-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-09-06 | Eingeleitet | HSBC Securities | Reduce |
| 2023-07-24 | Bestätigt | Barclays | Equal Weight |
| 2023-05-16 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-01-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | Fortgesetzt | BofA Securities | Neutral |
| 2022-12-09 | Herabstufung | DZ Bank | Buy → Hold |
| 2022-10-31 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2022-10-28 | Bestätigt | BMO Capital Markets | Market Perform |
| 2022-10-28 | Bestätigt | Cowen | Outperform |
| 2022-10-28 | Bestätigt | JP Morgan | Overweight |
| 2022-10-28 | Bestätigt | Jefferies | Buy |
| 2022-10-28 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-10-28 | Hochstufung | Truist | Hold → Buy |
| 2022-10-28 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-10-04 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-02-28 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | Bestätigt | BMO Capital Markets | Outperform |
| 2022-02-02 | Bestätigt | BofA Securities | Neutral |
| 2022-02-02 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-02-02 | Bestätigt | Truist | Hold |
| 2022-02-02 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-01-28 | Hochstufung | Argus | Hold → Buy |
| 2022-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | Fortgesetzt | Piper Sandler | Neutral |
| 2021-10-20 | Fortgesetzt | Cowen | Outperform |
| 2021-07-30 | Bestätigt | BMO Capital Markets | Market Perform |
| 2021-07-30 | Bestätigt | RBC Capital Mkts | Outperform |
| 2021-04-01 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | Hochstufung | Redburn | Neutral → Buy |
| 2021-01-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-11-03 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-09-30 | Fortgesetzt | Jefferies | Buy |
| 2020-09-15 | Hochstufung | Maxim Group | Hold → Buy |
| 2020-07-31 | Bestätigt | Credit Suisse | Neutral |
| 2020-07-31 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2020-07-31 | Bestätigt | Piper Sandler | Overweight |
| 2020-07-31 | Bestätigt | RBC Capital Mkts | Outperform |
| 2020-07-31 | Bestätigt | SunTrust | Hold |
| 2020-07-31 | Bestätigt | Wells Fargo | Equal Weight |
| 2020-07-20 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | Hochstufung | SunTrust | Sell → Hold |
| 2020-05-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-05-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | Herabstufung | SunTrust | Hold → Sell |
| 2020-04-27 | Herabstufung | UBS | Buy → Neutral |
| 2020-04-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Herabstufung | CFRA | Hold → Sell |
Alle ansehen
Gilead Sciences Inc Aktie (GILD) Neueste Nachrichten
Gilead Sciences (GILD) Announces Issuance of Senior Notes in New Indenture Agreement - GuruFocus
Gilead Sciences Launches New $3 Billion Senior Notes - TipRanks
Gilead Sciences issues $3 billion in senior notes across four tranches - StreetInsider
Gilead Sciences (GILD) prices multiple senior note series due 2028–2034 - Stock Titan
GILD Maintains a $122 Price Target Following Healthcare Conferen - GuruFocus
Gilead Sciences (NASDAQ:GILD) Upgraded to Buy at Maxim Group - MarketBeat
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance Singapore
Maxim Upgrades Gilead Sciences to Buy From Hold, Price Target Is $165 - Moomoo
Maxim Group Upgrades Gilead Sciences(GILD.US) to Buy Rating, Announces Target Price $165 - Moomoo
Morgan Stanley Reassesses Gilead Sciences (GILD) Outlook Following Quarterly Report - Yahoo! Finance Canada
Jag Capital Management LLC Buys New Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Sold by Mitsubishi UFJ Asset Management UK Ltd. - MarketBeat
Fideuram Intesa Sanpaolo Private Banking S.P.A. Takes $50.80 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Sold by Banque Cantonale Vaudoise - MarketBeat
Atle Fund Management AB Sells 27,373 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Yuhan expands API deals with Gilead, boosts South Korea productionCHOSUNBIZ - Chosunbiz
Yuhan Signs 210.2 Billion Won API Supply Deal with Gilead - Seoul Economic Daily
When Every Moment Matters: Kite’s CAR T-cell Therapy Helps Bring Hope to Patients - Gilead Sciences
Oorja Bio Launches as a Clinical-Stage Company to Develop Groundbreaking Therapies for Idiopathic Pulmonary Fibrosis (IPF) and Other Fibrotic Diseases - GlobeNewswire Inc.
Argus Research Sticks to Its Buy Rating for Gilead Sciences (GILD) - The Globe and Mail
Gilead Sciences to buy clinical-stage biotech Tubulis for up to $5 billion - MSN
Daiwa Securities Group Issues Pessimistic Forecast for Gilead Sciences (NASDAQ:GILD) Stock Price - MarketBeat
Resona Asset Management Co. Ltd. Lowers Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Profund Advisors LLC Buys 15,824 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
ProShare Advisors LLC Buys 623,752 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences (NASDAQ:GILD) Screens as a Top Dividend Stock with Strong Profitability and Health - ChartMill
Gilead Sciences Q1 2026 Earnings: Revenue Beat, Raised Guidance, and Key Analyst QuestionsNews and Statistics - IndexBox
Handelsbanken Fonder AB Sells 81,694 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
HighTower Advisors LLC Decreases Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Latham & Watkins Advises on Gilead Sciences’ US$3 Billion Senior Unsecured Notes Offering - Legal Desire
MacroGenics stock (US5562221046): biotech shares jump after Vyloy FDA approval and takeover deal - AD HOC NEWS
Insider Sell Alert: Andrew Dickinson Sells Shares of Gilead Scie - GuruFocus
Gilead Sciences Inc (GILD) Stock Price, Trades & News - GuruFocus
Gilead Sciences (NASDAQ:GILD) Insider Sells $3,676,120.00 in Stock - MarketBeat
Gilead Sciences CFO Andrew Dickinson sells $396,810 in stock By Investing.com - Investing.com Australia
Gilead Sciences Insider Sold Shares Worth $3,676,199, According to a Recent SEC Filing - Moomoo
Gilead Sciences chief comm officer sells $3.68m of stock By Investing.com - Investing.com UK
Gilead Sciences chief comm officer sells $3.68m of stock - Investing.com
Gilead Sciences CFO Andrew Dickinson sells $396,810 in stock - Investing.com India
Gilead (GILD) CFO Andrew Dickinson sells 3,000 shares under 10b5-1 plan - Stock Titan
Gilead (GILD) executive sells 28,000 shares, exercises 25,000 options - Stock Titan
Gilead Sciences (NASDAQ: GILD) sells $3.0B of senior notes due 2028–2034 - Stock Titan
Cipla Flips Gilead’s ‘End Run’ Claim in Descovy Patent Fight - Bloomberg Law News
Gilead Sciences prices $3B multi-tranche senior notes offering - MSN
Gilead Sciences’s Q1 Earnings Call: Our Top 5 Analyst Questions - Yahoo Finance
WealthPlan Investment Management LLC Acquires 10,256 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
TD Private Client Wealth LLC Acquires 17,944 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
45,461 Shares in Gilead Sciences, Inc. $GILD Purchased by North Dakota State Investment Board - MarketBeat
Gilead Sciences, Inc. (GILD) Stock Analysis: Evaluating a 21.90% Upside Potential for Investors - DirectorsTalk Interviews
Erste Group Bank Predicts Gilead Sciences FY2026 Earnings - MarketBeat
Gilead Sciences Inc stock (US3755581036): dividend growth and HIV/oncology pipeline in focus - AD HOC NEWS
Finanzdaten der Gilead Sciences Inc-Aktie (GILD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
1.09%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):